AskBio Begins Phase II Gene Therapy Trial for Parkinson’s in Europe
- SSCTR Exco
- Oct 4
- 1 min read
Published on Bayer
Bayer’s AskBio has randomized the first European participants in its Phase II trial of AB-1005, an investigational gene therapy for Parkinson’s disease. The therapy delivers the GDNF gene directly to targeted brain regions with the aim of protecting and restoring dopamine neurons, offering a potential disease-modifying approach.
👉 Read the full article: First European Participants Randomized in AskBio Phase 2 Gene Therapy Trial of AB-1005 for Parkinson’s Disease
Disclaimer
Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full detail, refer to the original article via the provided link. SSCTR does not provide medical advice, and the views expressed are for educational purposes only.
Comments